Threshold Pharmaceuticals, Inc (THLD): Opiniones

http://nasdaqlandia.com/thld-threshold-pharmaceuticals-inc-continua-su-peregrinaje-actu-14112014.html

NVAX y THLD las dos favoritas del super, las que más ponderan en toda mi cartera con diferencia, espero acierte en lo que dice:)

http://www.thelifesciencesreport.com/pub/co/4663?utm_source=delivra&utm_medium=email&utm_campaign=SW+Comp+Final+11-14-14

Threshold Pharmaceuticals Announces Phase 1/2 Interim Data Signaling Activity of TH-302 Plus Bevacizumab (Avastin(R)) in Patients With Glioblastoma
64% of Patients Achieved Stable Disease or Tumor Shrinkage on Combination Therapy Following Progression on Single-Agent Bevacizumab; U.S. FDA Set to Fund Phase 2 Investigator-Sponsored Trial
As reported by the investigator, in a total of 22 evaluable patients, best responses included one complete response and three partial responses for a response rate of 18%, and ten stable disease assessments for a clinical benefit rate of 64%; eight patients had progressive disease. Median progression-free survival was 2.8 months, and median overall survival was 4.6 months.
.
http://finance.yahoo.com/news/threshold-pharmaceuticals-announces-phase-1-120000474.html

juraria que la semana pesada vi el institucional de este valor en 47%

Hoy ya marca el 53%

espero no ser el unico que se a quedado..... :-( ...pero voy a ser yo quien haga la pregunta .... framus ...eso que es ??

....ya creo haber encontrado algo gracias.

y creo que no es malo para el valor no ??

el % de acciones que tienen los fondos e instituciones con respecto al free float , el total de acciones disponibles.

Cantor Fitzgerald Reaffirms Buy On Threshold Pharmaceuticals Following Strong GBM Data

http://www.smarteranalyst.com/2014/11/18/cantor-fitzgerald-reaffirms-buy-on-threshold-pharmaceuticals-following-strong-gbm-data/

reitera precio objetivo 14$

"In a research note released today, Cantor Fitzgerald analyst Daniel Brims reaffirmed a Buy rating on Threshold Pharmaceuticals (NASDAQ:THLD) with a $14 price target, following the company’s release of glioblastoma data, which has continued to demonstrate TH302’s efficacy.

Brims wrote, “We believe these results compared favorably with historical PFS and OS of ~1 month and 3 months respectively, strengthening our confidence that TH-302 can fill an unmet need in GBM and has efficacy in solid tumors.”

The analyst continued, “Dr. Brenner has received a grant from the FDA’s Office of Orphan Product Development in order to conduct a phase 3 trial of TH-302 and bevacizumab in 33 bevacizumab failure patients. Dr. Brenner’s grant is only one of 15 awarded this year by the FDA, demonstrating the significant unmet medical need in this patient population and the compelling nature of the phase 1/2 data collected to date. Historically, phase 2 data has been sufficient to gain regulatory approval and, while it is still unclear what endpoints FDA would accept (overall response rate, overall survival, or quality of life) for review, we expect this study, which could initiate as early as YE:14, to support an NDA filing.”